Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia

Authors: Taher Chharchhodawala, Smeeta Gajendra, Priya Tiwari, Ajay Gogia, Ritu Gupta

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

Acute myeloid leukemia (AML) with t(8;16)(p11;q13) is a distinct clinical and morphological entity with poor prognosis, which is characterized by a high frequency of extramedullary involvement, most commonly leukemia cutis; association with therapy related AML; frequent coagulopathy and morphologic features overlapping acute promyelocytic leukemia(APL). Herein, we present a case of 47 year-old post-menopausal woman developing secondary AML with t(8;16)(p11;q13) after 1 year of completion of therapy for breast carcinoma. Blasts were granulated with few showing clefted nucleus resembling promyelocytes and immnuophenotyping showed high side scatter with MPO positivity and CD 34 and HLA-DR negativity. In view of promyelocyte like morphology and immunophenotyping of blasts, possibility of APL was considered but, reverse transcription polymerase chain reaction (RT-PCR) for PML-RARα fusion transcript came out to be negative. Conventional cytogenetics showed t(8;16)(p11;q13). So, we should keep possibility of t(8;16) (p11;q13) in therapy related acute myeloid leukemia in patient showing clinical and morphological features of acute promyelocytic leukemia.
Literature
1.
go back to reference Gervais C, Murati A, Helias C et al (2008) Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia 22:1567–1575CrossRefPubMed Gervais C, Murati A, Helias C et al (2008) Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia 22:1567–1575CrossRefPubMed
2.
go back to reference Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G (2011) Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. Crit Rev Oncol Hematol 80:331–346CrossRefPubMed Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G (2011) Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. Crit Rev Oncol Hematol 80:331–346CrossRefPubMed
3.
go back to reference Haferlach T, Kohlmann A, Klein HU et al (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943CrossRefPubMed Haferlach T, Kohlmann A, Klein HU et al (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943CrossRefPubMed
4.
go back to reference Diab A, Zickl L, Abdel-Wahab O et al (2013) Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res 37:32–36CrossRefPubMed Diab A, Zickl L, Abdel-Wahab O et al (2013) Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res 37:32–36CrossRefPubMed
5.
go back to reference Daifu T, Kato I, Kozuki K et al (2014) The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia. J Pediatr Hematol Oncol 36(5):e325–e327CrossRefPubMed Daifu T, Kato I, Kozuki K et al (2014) The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia. J Pediatr Hematol Oncol 36(5):e325–e327CrossRefPubMed
6.
go back to reference Coenen EA, Zwaan CM, Reinhardt D et al (2013) Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 122(15):2704–2713CrossRefPubMedPubMedCentral Coenen EA, Zwaan CM, Reinhardt D et al (2013) Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 122(15):2704–2713CrossRefPubMedPubMedCentral
7.
go back to reference Bernasconi P, Orlandi E, Cavigliano P et al (2000) Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin’s lymphoma. Haematologica 85(10):1087–1091PubMed Bernasconi P, Orlandi E, Cavigliano P et al (2000) Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin’s lymphoma. Haematologica 85(10):1087–1091PubMed
8.
go back to reference Rozman M, Camós M, Colomer D et al (2004) Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer 40(2):140–145CrossRefPubMed Rozman M, Camós M, Colomer D et al (2004) Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer 40(2):140–145CrossRefPubMed
Metadata
Title
Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia
Authors
Taher Chharchhodawala
Smeeta Gajendra
Priya Tiwari
Ajay Gogia
Ritu Gupta
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0527-0

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine